Screener
Discontinued — last reported Q4 '25
CapEx at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Cullinan Therapeutics, Inc.’s 10-K, filed March 10, 2026.
- Filed
- Mar 10, 2026, 7:26 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-099362
| Line item | 2025 | 2024 |
|---|---|---|
| Investing activities: | ||
| Maturities of marketable securities | 416,572 | 584,817 |
| Purchase of marketable securities | (236,534) | (721,131) |
| Purchase of property and equipment | (49) | — |
| Net cash provided by (used in) investing activities | 179,989 | (136,314) |
| Financing activities: | ||
| Issuance of common stock under equity-based compensation plans | 1,088 | 7,984 |
| Issuance of common stock and pre-funded warrants, net of issuance costs | — | 262,652 |
Item 16. Form 10-K Summary.
FAQ
- What is Cullinan Therapeutics, Inc.'s capex?
- Cullinan Therapeutics, Inc. (CGEM) reported capex of $11K in Q4 2025.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Cullinan Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude